Search

Your search keyword '"Christy-Bittel, J."' showing total 5 results
Start Over Author "Christy-Bittel, J." Journal annals of oncology
5 results on '"Christy-Bittel, J."'

1. LBA-7 Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic antigen (CEA) and clinical outcomes from BEACON CRC

Author

Grothey, A., primary, Kopetz, S., additional, Yaeger, R., additional, Van Cutsem, E., additional, Wasan, H., additional, Desai, J., additional, Ciardiello, F., additional, Yoshino, T., additional, Maharry, K., additional, Christy-Bittel, J., additional, Gollerkeri, A., additional, and Tabernero, J., additional

Published
2020
Full Text
View/download PDF

2. BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer

Author

Kopetz, S., primary, Grothey, A., additional, Van Cutsem, E., additional, Yaeger, R., additional, Wasan, H., additional, Yoshino, T., additional, Desai, J., additional, Ciardiello, F., additional, Gollerkeri, A., additional, Maharry, K., additional, Loupakis, F., additional, Hong, Y., additional, Steeghs, N., additional, Guren, T., additional, Arkenau, H., additional, García Alfonso, P., additional, Sandor, V., additional, Christy-Bittel, J., additional, Anderson, L., additional, and Tabernero, J., additional

Published
2019
Full Text
View/download PDF

3. BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti–epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer

Author

Van Cutsem, E., primary, Cuyle, P., additional, Huijberts, S., additional, Schellens, J., additional, Elez, E., additional, Yaeger, R., additional, Fakih, M., additional, Montagut, C., additional, Peeters, M., additional, Desai, J., additional, Yoshino, T., additional, Ciardiello, F., additional, Wasan, H., additional, Maharry, K., additional, Christy-Bittel, J., additional, Gollerkeri, A., additional, Kopetz, S., additional, Grothey, A., additional, and Tabernero, J., additional

Published
2018
Full Text
View/download PDF

4. LBA-006 - BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer

Author

Kopetz, S., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Gollerkeri, A., Maharry, K., Loupakis, F., Hong, Y., Steeghs, N., Guren, T., Arkenau, H., García Alfonso, P., Sandor, V., Christy-Bittel, J., Anderson, L., and Tabernero, J.

Published
2019
Full Text
View/download PDF

5. O-027 - BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib + MEK inhibitor binimetinib + anti–epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer

Author

Van Cutsem, E., Cuyle, P., Huijberts, S., Schellens, J., Elez, E., Yaeger, R., Fakih, M., Montagut, C., Peeters, M., Desai, J., Yoshino, T., Ciardiello, F., Wasan, H., Maharry, K., Christy-Bittel, J., Gollerkeri, A., Kopetz, S., Grothey, A., and Tabernero, J.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results